AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home iLIVER Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Aspirin in hepatocellular carcinoma: Is it an out-of-date or promising treatment?

Xun Qiua,1, Fengqiang Gaoa,1, Kai Wanga, Zhensheng Zhanga, Chuxiao Shaoe, Xiao Xua,b,c,d ( )
Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China
Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, 310024, China
NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, 310003, China
Institute of Organ Transplantation, Zhejiang University, Hangzhou, 310003, China
Department of Hepatobiliary and Pancreatic Surgery, Affiliated Lishui Hospital, Zhejiang University School of Medicine, Lishui, 323000, China

1 These authors contributed equally to this work.

Show Author Information

Abstract

Hepatocellular carcinoma (HCC) is one of the most aggressive human malignancies with a dismal survival rate. Few strategies can effectively prevent the occurrence of HCC. Although immunotherapy has significantly improved HCC-related survival in recent years, this systemic therapy is very expensive and lays a heavy burden on most HCC patients. Aspirin, which is currently one of the most widely used medications in analgesic and cardiovascular diseases, is reported to have anti-tumor effects on HCC. Most importantly, long-term administration of low-dose aspirin does not significantly increase the risk of gastrointestinal bleeding. Owing to its cost-effectiveness and wide use, aspirin can be easily applied as an HCC treatment and is affordable for a wide range of patients. Therefore, deeper understanding and more attention are needed to extend the frontline of aspirin's preventive and therapeutic potential into cancer research and management. In this review, we discuss the preventive effect of aspirin on HCC in the context of different etiological factors, including hepatitis B or hepatitis C virus infection, non-alcoholic fatty liver disease, and alcohol-associated liver disease. The therapeutic role of aspirin in resectable or unresectable HCC management is also discussed. Furthermore, the mechanisms underlying the anti-cancer effects of aspirin on HCC are fully reviewed and discussed in the following two aspects: the effect of aspirin on multi-oncogenic signaling pathways in HCC (e.g., AMPK, Wnt/β-catenin, NF-κB) and aspirin-mediated immunometabolic responses in liver diseases. These findings indicate aspirin is a promising agent for populations at risk and HCC patients to prevent or treat HCC.

Keywords

Hepatocellular carcinomaAspirinChemopreventionCancer therapyOncogenic signalingImmunometabolic response

References

[1]

Villanueva A. Hepatocellular carcinoma. N. Engl. J. Med. 2019;380: 1450–62. https://doi.org/10.1056/NEJMra1713263.
Crossref Google Scholar
[2]

Yang D, Luo W, Wang J, et al. A novel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways. J. Contr. Release 2018;269: 405–22. https://doi.org/10.1016/j.jconrel.2017.11.031.
Crossref Google Scholar
[3]

Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391: 1301–14. https://doi.org/10.1016/S0140-6736(18)30010-2.
Crossref Google Scholar
[4]

Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J. Hepatol. 2019;70: 151–71. https://doi.org/10.1016/j.jhep.2018.09.014.
Crossref Google Scholar
[5]

Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379: 1245–55. https://doi.org/10.1016/S0140-6736(11)61347-0.
Crossref Google Scholar
[6]

Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 2022;19: 151–72. https://doi.org/10.1038/s41571-021-00573-2.
Crossref Google Scholar
[7]

Hua H, Zhang H, Kong Q, Wang J, Jiang Y. Complex roles of the old drug aspirin in cancer chemoprevention and therapy. Med. Res. Rev. 2019;39: 114–45. https://doi.org/10.1002/med.21514.
Crossref Google Scholar
[8]

Simon TG, Duberg AS, Aleman S, Chung RT, Chan AT, Ludvigsson JF. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N. Engl. J. Med 2020;382: 1018–28. https://doi.org/10.1056/NEJMoa1912035.
Crossref Google Scholar
[9]

Cao Y, Nishihara R, Wu K, et al. Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol. 2016;2: 762–9. https://doi.org/10.1001/jamaoncol.2015.6396.
Crossref Google Scholar
[10]

Shin S, Lee SH, Lee M, et al. Aspirin and the risk of hepatocellular carcinoma development in patients with alcoholic cirrhosis. Medicine (Baltim) 2020;99: e19008. https://doi.org/10.1097/MD.0000000000019008.
Crossref Google Scholar
[11]

Simon TG, Henson J, Osganian S, et al. Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2019;17: 2776–84. https://doi.org/10.1016/j.cgh.2019.04.061.e4.
Crossref Google Scholar
[12]

Li JH, Wang Y, Xie XY, et al. Aspirin in combination with TACE in treatment of unresectable HCC: a matched-pairs analysis. Am. J. Cancer Res. 2016;6: 2109–16.
Google Scholar
[13]

Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012;308: 1906–14. https://doi.org/10.1001/2012.jama.11975.
Crossref Google Scholar
[14]

Liu YX, Feng JY, Sun MM, et al. Aspirin inhibits the proliferation of hepatoma cells through controlling GLUT1-mediated glucose metabolism. Acta Pharmacol. Sin. 2019;40: 122–32. https://doi.org/10.1038/s41401-018-0014-x.
Crossref Google Scholar
[15]

Shi T, Fujita K, Gong J, et al. Aspirin inhibits hepatocellular carcinoma cell proliferation in vitro and in vivo via inducing cell cycle arrest and apoptosis. Oncol. Rep. 2020;44: 457–68. https://doi.org/10.3892/or.2020.7630.
Crossref Google Scholar
[16]

Abiru S, Nakao K, Ichikawa T, et al. Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology 2002;35: 1117–24. https://doi.org/10.1053/jhep.2002.32676.
Crossref Google Scholar
[17]

Yang G, Wang Y, Feng J, et al. Aspirin suppresses the abnormal lipid metabolism in liver cancer cells via disrupting an NFkappaB-ACSL1 signaling. Biochem Biophys Res Commun. 2017;486: 827–32. https://doi.org/10.1016/j.bbrc.2017.03.139.
Crossref Google Scholar
[18]

Ren J, Meng S, Yan B, Yu J, Liu J. Protectin D1 reduces concanavalin A-induced liver injury by inhibiting NF-kappaB-mediated CX3CL1/CX3CR1 axis and NLR family, pyrin domain containing 3 inflammasome activation. Mol. Med. Rep. 2016; 13: 3627–38. https://doi.org/10.3892/mmr.2016.4980.
Crossref Google Scholar
[19]

Desborough M, Keeling DM. The aspirin story - from willow to wonder drug. Br. J. Haematol. 2017;177: 674–83. https://doi.org/10.1111/bjh.14520.
Crossref Google Scholar
[20]

Ardoino I, Rossio R, Di Blanca D, et al. Appropriateness of antiplatelet therapy for primary and secondary cardio- and cerebrovascular prevention in acutely hospitalized older people. Br. J. Clin. Pharmacol. 2017;83: 2528–40. https://doi.org/10.1111/bcp.13355.
Crossref Google Scholar
[21]
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 2017;67: 370–98. https://doi.org/10.1016/j.jhep.2017.03.021.
Crossref
[22]

Zhang X, Guan L, Tian H, et al. Risk factors and prevention of viral hepatitis-related hepatocellular carcinoma. Front. Oncol. 2021;11: 686962. https://doi.org/10.3389/fonc.2021.686962.
Crossref Google Scholar
[23]

Yin P, Zhang L. Aspirin inhibits hepatitis C virus entry by downregulating claudin-1. J. Viral Hepat. 2016;23: 62–4. https://doi.org/10.1111/jvh.12446.
Crossref Google Scholar
[24]

Trujillo-Murillo K, Rincon-Sanchez AR, Martinez-Rodriguez H, et al. Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways. Hepatology 2008;47: 1462–72. https://doi.org/10.1002/hep.22215.
Crossref Google Scholar
[25]

Rios-Ibarra CP, Lozano-Sepulveda S, Munoz-Espinosa L, Rincon-Sanchez AR, Cordova-Fletes C, Rivas-Estilla AM. Downregulation of inducible nitric oxide synthase (iNOS) expression is implicated in the antiviral activity of acetylsalicylic acid in HCV-expressing cells. Arch. Virol. 2014;159: 3321–8. https://doi.org/10.1007/s00705-014-2201-5.
Crossref Google Scholar
[26]

Rivas-Estilla AM, Bryan-Marrugo OL, Trujillo-Murillo K, et al. Cu/Zn superoxide dismutase (SOD1) induction is implicated in the antioxidative and antiviral activity of acetylsalicylic acid in HCV-expressing cells. Am. J. Physiol. Gastrointest Liver Physiol. 2012;302: G1264–73. https://doi.org/10.1152/ajpgi.00237.2011.
Crossref Google Scholar
[27]

Lee TY, Hsu YC, Tseng HC, et al. Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B. JAMA Intern. Med. 2019;179: 633–40. https://doi.org/10.1001/jamainternmed.2018.8342.
Crossref Google Scholar
[28]

Jang H, Lee YB, Moon H, et al. Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. Hepatology 2022. https://doi.org/10.1002/hep.32380.
Crossref Google Scholar
[29]

Lee TY, Hsu YC, Tseng HC, Lin JT, Wu MS, Wu CY. Association of daily aspirin therapy with hepatocellular carcinoma risk in patients with chronic hepatitis C virus infection. Clin. Gastroenterol. Hepatol. 2020;18: 2784–92. https://doi.org/10.1016/j.cgh.2020.04.036.e7.
Crossref Google Scholar
[30]

Liao YH, Hsu RJ, Wang TH, et al. Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study. BMC Gastroenterol. 2020;20: 6. https://doi.org/10.1186/s12876-020-1158-y.
Crossref Google Scholar
[31]

Yi M, Feng X, Peng W, Teng F, Tang Y, Chen Z. Aspirin for the prevention of hepatocellular carcinoma: an updated meta-analysis with particular focus on patients with chronic liver disease. Eur. J. Clin. Pharmacol. 2022. https://doi.org/10.1007/s00228-021-03247-1.
Crossref Google Scholar
[32]

Li X, Wu S, Yu Y. Aspirin use and the incidence of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis of cohort studies. Front. Med. 2020;7: 569759. https://doi.org/10.3389/fmed.2020.569759.
Crossref Google Scholar
[33]

Liu Y, Chang CC, Marsh GM, Wu F. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur. J. Cancer. 2012;48: 2125–36. https://doi.org/10.1016/j.ejca.2012.02.009.
Crossref Google Scholar
[34]

Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397: 2212–24. https://doi.org/10.1016/S0140-6736(20)32511-3.
Crossref Google Scholar
[35]

Ganne-Carrie N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J. Hepatol. 2019;70: 284–93. https://doi.org/10.1016/j.jhep.2018.10.008.
Crossref Google Scholar
[36]

Han YM, Lee YJ, Jang YN, et al. Aspirin improves nonalcoholic fatty liver disease and atherosclerosis through regulation of the PPARdelta-AMPK-PGC-1alpha pathway in dyslipidemic conditions. BioMed Res. Int. 2020;2020: 7806860. https://doi.org/10.1155/2020/7806860.
Crossref Google Scholar
[37]

Zhou Y, Peng H, Liu Z, et al. Sex-associated preventive effects of low-dose aspirin on obesity and non-alcoholic fatty liver disease in mouse offspring with over-nutrition in utero. Lab. Invest. 2019;99: 244–59. https://doi.org/10.1038/s41374-018-0144-2.
Crossref Google Scholar
[38]

Malehmir M, Pfister D, Gallage S, et al. Platelet GPIbalpha is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat. Med. 2019;25: 641–55. https://doi.org/10.1038/s41591-019-0379-5.
Crossref Google Scholar
[39]

Liu Y, Nong L, Jia Y, et al. Aspirin alleviates hepatic fibrosis by suppressing hepatic stellate cells activation via the TLR4/NF-kappaB pathway. Aging (Albany NY) 2020; 12: 6058–66. https://doi.org/10.18632/aging.103002.
Crossref Google Scholar
[40]

Li CJ, Yang ZH, Shi XL, Liu DL. Effects of aspirin and enoxaparin in a rat model of liver fibrosis. World J. Gastroenterol. 2017;23: 6412–9. https://doi.org/10.3748/wjg.v23.i35.6412.
Crossref Google Scholar
[41]

Jiang ZG, Feldbrugge L, Tapper EB, et al. Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. Aliment Pharmacol. Ther. 2016;43: 734–43. https://doi.org/10.1111/apt.13515.
Crossref Google Scholar
[42]

Sahasrabuddhe VV, Gunja MZ, Graubard BI, et al. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J. Natl. Cancer Inst. 2012;104: 1808–14. https://doi.org/10.1093/jnci/djs452.
Crossref Google Scholar
[43]

Petrick JL, Sahasrabuddhe VV, Chan AT, et al. NSAID use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the liver cancer pooling project. Cancer Prev. Res. 2015;8: 1156–62. https://doi.org/10.1158/1940-6207.CAPR-15-0126.
Crossref Google Scholar
[44]

Lee M, Chung GE, Lee JH, et al. Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. Hepatology 2017; 66: 1556–69. https://doi.org/10.1002/hep.29318.
Crossref Google Scholar
[45]

Simon TG, Ma Y, Ludvigsson JF, et al. Association between aspirin use and risk of hepatocellular carcinoma. JAMA Oncol. 2018;4: 1683–90. https://doi.org/10.1001/jamaoncol.2018.4154.
Crossref Google Scholar
[46]

Hwang IC, Chang J, Kim K, Park SM. Aspirin use and risk of hepatocellular carcinoma in a national cohort study of Korean adults. Sci. Rep. 2018;8: 4968. https://doi.org/10.1038/s41598-018-23343-0.
Crossref Google Scholar
[47]

Du ZQ, Zhao JZ, Dong J, et al. Effect of low-dose aspirin administration on longterm survival of cirrhotic patients after splenectomy: a retrospective single-center study. World J. Gastroenterol. 2019;25: 3798–807. https://doi.org/10.3748/wjg.v25.i28.3798.
Crossref Google Scholar
[48]

Choi WM, Kim HJ, Jo AJ, et al. Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: a nationwide population-based study. Liver. Int. 2021;41: 2777–85. https://doi.org/10.1111/liv.15011.
Crossref Google Scholar
[49]

Hui VW, Yip TC, Wong VW, et al. Aspirin reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis B receiving oral nucleos(t)ide analog. Clin. Transl. Gastroenterol. 2021;12: e00324. https://doi.org/10.14309/ctg.0000000000000324.
Crossref Google Scholar
[50]

Singh J, Wozniak A, Cotler SJ, et al. Combined use of aspirin and statin is associated with a decreased incidence of hepatocellular carcinoma. J. Clin. Gastroenterol. 2022;56: 369–73. https://doi.org/10.1097/MCG.0000000000001546.
Crossref Google Scholar
[51]

Young SH, Chau GY, Lee IC, et al. Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. J. Formos. Med. Assoc. 2020;119: 218–29. https://doi.org/10.1016/j.jfma.2019.04.018.
Crossref Google Scholar
[52]

Lee PC, Yeh CM, Hu YW, et al. Antiplatelet therapy is associated with a better prognosis for patients with hepatitis B virus-related hepatocellular carcinoma after liver resection. Ann. Surg. Oncol. 2016;23: 874–83. https://doi.org/10.1245/s10434-016-5520-9.
Crossref Google Scholar
[53]

Boas FE, Brown KT, Ziv E, et al. Aspirin is associated with improved liver function after embolization of hepatocellular carcinoma. AJR Am. J. Roentgenol. 2019;213: 1–7. https://doi.org/10.2214/AJR.18.20846.
Crossref Google Scholar
[54]

Casadei-Gardini A, Rovesti G, Dadduzio V, et al. Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib. HPB 2021; 23: 915–20. https://doi.org/10.1016/j.hpb.2020.09.024.
Crossref Google Scholar
[55]

Hayashi T, Shibata M, Oe S, Miyagawa K, Honma Y, Harada M. Antiplatelet therapy improves the prognosis of patients with hepatocellular carcinoma. Cancers 2020; 12. https://doi.org/10.3390/cancers12113215.
Crossref Google Scholar
[56]

Ielasi L, Tovoli F, Tonnini M, et al. Beneficial prognostic effects of aspirin in patients receiving sorafenib for hepatocellular carcinoma: a tale of multiple confounders. Cancers 2021;13. https://doi.org/10.3390/cancers13246376.
Crossref Google Scholar
[57]

Wang T, Fu X, Jin T, et al. Aspirin targets P4HA2 through inhibiting NF-kappaB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma. EBioMedicine 2019;45: 168–80. https://doi.org/10.1016/j.ebiom.2019.06.048.
Crossref Google Scholar
[58]

Sun D, Liu H, Dai X, et al. Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition. Cancer Lett. 2017;406: 105–15. https://doi.org/10.1016/j.canlet.2017.06.029.
Crossref Google Scholar
[59]

Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004;23: 9247–58. https://doi.org/10.1038/sj.onc.1208169.
Crossref Google Scholar
[60]

Poorani R, Bhatt AN, Dwarakanath BS, Das UN. COX-2, aspirin and metabolism of arachidonic, eicosapentaenoic and docosahexaenoic acids and their physiological and clinical significance. Eur. J. Pharmacol. 2016;785: 116–32. https://doi.org/10.1016/j.ejphar.2015.08.049.
Crossref Google Scholar
[61]

Echeverria F, Valenzuela R, Espinosa A, et al. Reduction of high-fat diet-induced liver proinflammatory state by eicosapentaenoic acid plus hydroxytyrosol supplementation: involvement of resolvins RvE1/2 and RvD1/2. J. Nutr. Biochem. 2019;63: 35–43. https://doi.org/10.1016/j.jnutbio.2018.09.012.
Crossref Google Scholar
[62]

Gu Z, Lamont GJ, Lamont RJ, Uriarte SM, Wang H, Scott DA. Resolvin D1, resolvin D2 and maresin 1 activate the GSK3beta anti-inflammatory axis in TLR4-engaged human monocytes. Innate. Immun. 2016;22: 186–95. https://doi.org/10.1177/1753425916628618.
Crossref Google Scholar
[63]

Zhang F, Yang H, Pan Z, et al. Dependence of resolvin-induced increases in corneal epithelial cell migration on EGF receptor transactivation. Invest. Ophthalmol. Vis. Sci. 2010;51: 5601–9. https://doi.org/10.1167/iovs.09-4468.
Crossref Google Scholar
[64]

Lim K, Han C, Dai Y, Shen M, Wu T. Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2. Mol. Cancer Ther. 2009;8: 3046–55. https://doi.org/10.1158/1535-7163.MCT-09-0551.
Crossref Google Scholar
[65]

Lim K, Han C, Xu L, Isse K, Demetris AJ, Wu T. Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids. Cancer Res. 2008;68: 553–60. https://doi.org/10.1158/0008-5472.CAN-07-2295.
Crossref Google Scholar
[66]

Xu G, Wang Y, Li W, et al. COX-2 forms regulatory loop with YAP to promote proliferation and tumorigenesis of hepatocellular carcinoma cells. Neoplasia 2018; 20: 324–34. https://doi.org/10.1016/j.neo.2017.12.004.
Crossref Google Scholar
[67]

Yuan Z, Zhao J, Wang Z, Ren G, Zhang Z, Ma G. Effects of aspirin on hepatocellular carcinoma and its potential molecular mechanism. J. BUON. 2020;25: 981–6.
Google Scholar
[68]

Cheng SY, Zhang H, Zhang M, et al. Prostaglandin E(2) receptor EP2 mediates Snail expression in hepatocellular carcinoma cells. Oncol. Rep. 2014;31:2099–106. https://doi.org/10.3892/or.2014.3074.
Crossref Google Scholar
[69]

Lu L, Sun HC, Zhang W, et al. Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma. PLoS One 2013;8:e65023. https://doi.org/10.1371/journal.pone.0065023.
Crossref Google Scholar
[70]

Lu L, Lu M, Pei Y, et al. Down-regulation of SDF1-alpha expression in tumor microenvironment is associated with aspirin-mediated suppression of the prometastasis effect of sorafenib in hepatocellular carcinoma. Acta Biochim. Biophys. Sin. 2015;47:988–96. https://doi.org/10.1093/abbs/gmv112.
Crossref Google Scholar
[71]

Tai Y, Zhang LH, Gao JH, et al. Suppressing growth and invasion of human hepatocellular carcinoma cells by celecoxib through inhibition of cyclooxygenase-2. Cancer Manag. Res. 2019;11:2831–48. https://doi.org/10.2147/CMAR.S183376.
Crossref Google Scholar
[72]

Dai H, Zhang S, Ma R, Pan L. Celecoxib inhibits hepatocellular carcinoma cell growth and migration by targeting PNO1. Med. Sci. Monit. 2019;25:7351–60. https://doi.org/10.12659/MSM.919218.
Crossref Google Scholar
[73]

Han YM, Lee YJ, Jang YN, et al. Aspirin improves nonalcoholic fatty liver disease and atherosclerosis through regulation of the PPARdelta-AMPK-PGC-1alpha pathway in dyslipidemic conditions. BioMed Res. Int. 2020;2020:7806860. https://doi.org/10.1155/2020/7806860.
Crossref Google Scholar
[74]
He Z, Peng Y, Duan W, et al. Aspirin regulates hepatocellular lipid metabolism by activating AMPK signaling pathway. 2015.https://doi.org/10.2131/jts.40.127
Crossref
[75]

Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 2007;25: 101–37. https://doi.org/10.1146/annurev.immunol.25.022106.141647.
Crossref Google Scholar
[76]

Laiglesia LM, Lorente-Cebrian S, Martinez-Fernandez L, et al. Maresin 1 mitigates liver steatosis in ob/ob and diet-induced obese mice. Int. J. Obes. 2018;42:572–9. https://doi.org/10.1038/ijo.2017.226.
Crossref Google Scholar
[77]

Jung TW, Kim HC, Abd EA, Jeong JH. Maresin 1 attenuates NAFLD by suppression of endoplasmic reticulum stress via AMPK-SERCA2b pathway. J. Biol. Chem. 2018; 293:3981–8. https://doi.org/10.1074/jbc.RA117.000885.
Crossref Google Scholar
[78]

Serhan CN, Maddox JF, Petasis NA, et al. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochem.-US 1995;34: 14609–15. https://doi.org/10.1021/bi00044a041.
Crossref Google Scholar
[79]

Romano M, Cianci E, Simiele F, Recchiuti A. Lipoxins and aspirin-triggered lipoxins in resolution of inflammation. Eur. J. Pharmacol. 2015;760:49–63. https://doi.org/10.1016/j.ejphar.2015.03.083.
Crossref Google Scholar
[80]

Takano T, Clish CB, Gronert K, Petasis N, Serhan CN. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15- epi-lipoxin A4 and novel lipoxin B4 stable analogues. J. Clin. Invest. 1998;101: 819–26. https://doi.org/10.1172/JCI1578.
Crossref Google Scholar
[81]

Gewirtz AT, Fokin VV, Petasis NA, Serhan CN, Madara JL. LXA4, aspirin-triggered 15-epi-LXA4, and their analogs selectively downregulate PMN azurophilic degranulation. Am. J. Physiol. 1999;276:C988–94. https://doi.org/10.1152/ajpcell.1999.276.4.C988.
Crossref Google Scholar
[82]

Jozsef L, Zouki C, Petasis NA, Serhan CN, Filep JG. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc. Natl. Acad. Sci. U S A 2002;99: 13266–71. https://doi.org/10.1073/pnas.202296999.
Crossref Google Scholar
[83]

Hachicha M, Pouliot M, Petasis NA, Serhan CN. Lipoxin (LX)A4 and aspirintriggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J. Exp. Med. 1999;189:1923–30. https://doi.org/10.1084/jem.189.12.1923.
Crossref Google Scholar
[84]

Li Y, Cai L, Wang H, et al. Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2. Oncogene 2011;30:3887–99. https://doi.org/10.1038/onc.2011.112.
Crossref Google Scholar
[85]

Rius B, Titos E, Moran-Salvador E, et al. Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis. FASEB J. 2014;28: 836–48. https://doi.org/10.1096/fj.13-235614.
Crossref Google Scholar
[86]

Lopategi A, Flores-Costa R, Rius B, et al. Frontline Science: specialized proresolving lipid mediators inhibit the priming and activation of the macrophage NLRP3 inflammasome. J. Leukoc. Biol. 2019;105:25–36. https://doi.org/10.1002/JLB.3HI0517-206RR.
Crossref Google Scholar
[87]

Xu M, Li J, Neves M, et al. GPIbalpha is required for platelet-mediated hepatic thrombopoietin generation. Blood 2018;132:622–34. https://doi.org/10.1182/blood-2017-12-820779.
Crossref Google Scholar
[88]

Li S, Dai W, Mo W, et al. By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma. Int. J. Cancer 2017;141:2571–84. https://doi.org/10.1002/ijc.31022.
Crossref Google Scholar
[89]

Ford RJ, Fullerton MD, Pinkosky SL, et al. Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. Biochem. J. 2015;468:125–32. https://doi.org/10.1042/BJ20150125.
Crossref Google Scholar
[90]

Vannini F, Chattopadhyay M, Kodela R, Rao P, Kashfi K. Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling. Redox Biol. 2015;6:318–25. https://doi.org/10.1016/j.redox.2015.08.014.
Crossref Google Scholar
[91]

Chattopadhyay M, Kodela R, Nath N, et al. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect. Biochem. Pharmacol. 2012;83:715–22. https://doi.org/10.1016/j.bcp.2011.12.018.
Crossref Google Scholar
[92]

Song JM, Upadhyaya P, Kassie F. Nitric oxide-donating aspirin (NO-Aspirin) suppresses lung tumorigenesis in vitro and in vivo and these effects are associated with modulation of the EGFR signaling pathway. Carcinogenesis 2018;39:911–20. https://doi.org/10.1093/carcin/bgy049.
Crossref Google Scholar
iLIVER
Volume 1 Issue 1,
March 2022
Pages 55-64
DOI: 10.1016/j.iliver.2022.03.003
Cite this article:
Qiu X, Gao F, Wang K, et al. Aspirin in hepatocellular carcinoma: Is it an out-of-date or promising treatment?. iLIVER, 2022, 1(1): 55-64. https://doi.org/10.1016/j.iliver.2022.03.003

1226

Views

1

Crossref

2

Scopus

Altmetrics
Received: 21 February 2022
Revised: 11 March 2022
Accepted: 14 March 2022
Published: 28 March 2022
© 2022 The Authors. Published by Elsevier Ltd on behalf of Tsinghua University Press.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Return